Mobile

A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Pro...

Update Il y a 4 ans
Reference: EUCTR2009-011018-51

A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Protoporphyria (EPP)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Primary objective: - To determine whether afamelanotide can reduce the severity of phototoxic reactions in patients with EPP.

Inclusion criteria

  • Erythropoietic Protoporphyria (EPP)

Links